Matrix metalloproteinases as stromal effecters of human carcinoma progression: Therapeutic implications

Matrix Biology

Volumn 15, Issue 8-9, 1997, Pages 535-541

  Basset, Paul ^a   Okada, Akiko ^a   Chenard, Marie Pierre ^b   Kannan, Rama ^a   Stoll, Isabelle ^a   Anglard, Patrick ^a   Bellocq, Jean Pierre ^b   Rio, Marie Christine ^a  

^a INSTITUT DE GÉNÉTIQUE ET DE BIOLOGIE MOLÉCULAIRE ET CELLULAIRE   (France)

^b HÔPITAL DE HAUTEPIERRE   (France)

Author keywords

Cancer progression; Extracellular proteinases; Metalloproteinase inhibitors; Metalloproteinases; Proteinase activators receptors; Tumor stroma

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC AGENT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; MEMBRANE RECEPTOR;

ARTICLE; CANCER CELL; CANCER GROWTH; CANCER INVASION; EXTRACELLULAR MATRIX; HUMAN; HUMAN CELL; PHENOTYPE; PRIORITY JOURNAL; STROMA CELL;

EID: 0030938479     PISSN: 0945053X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0945-053X(97)90028-7     Document Type: Short Survey

References (51)

1. Anglard P., Melot T., Guérin E., Thomas G., Basset P. Structure and promoter characterization of the human stromelysin-3 gene. J. Biol. Chem. 270:1995;20337-20344.
2. Benbow, U. and Brinckerhoff, C.E.: The AP-1 site and MMP gene regulations: What is all the fuss about? Matrix Biology, this issue.
3. Bond J.S., Beynon R.J. The astacin family of metalloendopeptidases. Protein Sci. 4:1995;1247-1261.
4. Brooks P.C., Strömblad S., Sanders L.C., von Schalscha T.L., Aimes R.T., Stetler-Stevenson W.G., Quigley J.P., Cheresh D.A. Localization of matrix metalloproteinase MMP-2 to the surface of invasive cells by interaction with integrin βvβ3. Cell. 85:1996;683-693.
5. Brown P.D., Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumour activity. Ann. Oncol. 6:1995;967-974.
6. Byrne J.A., Tomasetto C., Rouyer N., Bellocq J.P., Rio M.C., Basset P. The tissue inhibitor of metalloproteinases-3 gene in breast carcinoma: identification of multiple polyadenylation sites and a stromal pattern of expression. Mol. Med. 1:1995;418-427.
7. Chenard M.P., C'Siorain L., Shering S., Rouyer N., Lutz Y., Wolf O., Basset P., Bellocq J.P., Duffy M.J. High evels of stromelysin-3 correlate with poor prognosis in patients with breast carcinoma. Int. J. Cancer. 69:1996;448-451.
8. Duffy M.J. Proteases as prognostic markers in cancer. Clin. Cancer Res. 1996;613-618.
9. Dvorak H.E. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 31:1986;1650-1659.
10. Emmert-Buck M.R., Emonard H.P., Corcotan M.L., Krutzsch H.C., Foidart J.M., Stetler-Stevenson W.G. Cell surface binding of TIMP-2 and pro-MMP-2/TIMP-2 complex. FEBS Lett. 364:1995;28-32.
11. r 72,000 type IV collagenase. Cancer Res. 52:1992;5845-5848.
12. Engel G., Heselmeyer K., Auer G., Bäckdahl M., Eriksson E., Linder S. Correlation between stromelysin-3 mRNA level and outcome of human breast cancer. Int. J. Cancer. 58:1994;830-835.
13. Fanjul A., Dawson M.I., Hobbs P.D., Jong L., Cameron J.F., Harlev E., Graupner G., Lu X.P., Pfahl M. A new class of retinoids with selective inhibition of AP-1 inhibits proliferation. Nature. 372:1994;107-110.
14. Flaumenhaft R., Rifkin D. Extracellular matrix regulation of growth factor and protease activity. Curr. Opin. Cell Biol. 3:1991;817-823.
15. Fowlkes J.L., Enghild J.J., Suzuki K., Nagase H. Matrix metalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. 269:1994;25742-25746.
16. Gaire M., Magbanua Z., McDonnell S., McNeil L., Lovett D.H., Matrisian L.M. Structure and expression of the human gene for the matrix metalloproteinase matrilysin. J. Biol. Chem. 269:1994;2032-2040.
17. Gray S.T., Yun K., Motoori T., Kuys Y.M. Interstitial collagenase gene expression in colonic neoplasia. Am. J. Pathol. 143:1993;663-671.
18. Grøndahl-Hansen J., Christensen I.J., Rosenquist C., Brünner N., Mouridsen H.T., Danø K., Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 53:1993;2513-2521.
19. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenic. Cell. 86:1996;353-364.
20. Hendrix M.J.C., Wood W.R., Seftor E.A., Lotan D., Nakajima M., Misiorowski R.L., Seftor R.E.B., Stetler-Stevenson W.G., Bevacqua S.J., Liotta L.A., Sobel M.E., Raz A., Lotan R. Retinoic acid inhibition of human melanoma cell invasion through a reconstituted basement membrane and its relation to decreases in the expression of proteolytic enzymes and mobility factor receptor. Cancer Res. 50:1990;4121-4130.
21. Heppner K.J., Matrisian L.M., Jensen R.A., Rodgers W.H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am. J. Pathol. 149:1996;273-282.
22. Hewitt R.E., Leach I.H., Powe D.G., Clark I.M., Cawston T.E., Turner D.R. Distribution of collagenase and tissue inhibitor of metalloproteinases (TIMP) in colorectal tumours. Int. J. Cancer. 49:1991;666-672.
23. Hodgson J. Remodelling MMPIs. Biotechnology. 13:1995;554-557.
24. Höyhtyä M., Fridman R., Komarek D., Porter-Jordan K., Stetler-Stevenson G., Liotta L.A., Liang C.M. Immunohistochemical localization of matrix metalloproteinase 2 and its specific inhibitor TIMP-2 in neoplastic tissues with monoclonal antibodies. Int. J. Cancer. 56:1994;500-505.
25. Imai K., Ohuchi E., Aoki T., Nomura H., Fujii Y., Sato H., Seiki M., Okada Y. Membrane-type matrix metalloproteinase 1 is a gelatinolytic enzyme and is secreted in a complex with tissue inhibitor of metalloproteinases 2. Cancer Res. 56:1996;2707-2710.
26. Levi E., Fridman R., Miao H.Q., Ma Y.S., Yayon A., Vlodavsky I. Matrix metalloproteinase 2 release active solube ectodomain of fibroblast growth factor receptor 1. Proc. Natl Acad. Sci. USA. 93:1996;7069-7074.
27. Liotta L.A. Cancer cell invasion and metastasis. Sci. Am. 266:(2):1992;34-41.
28. MacDougall J.R., Matrisian L.M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metast. Rev. 14:1995;351-362.
29. Murphy, G. and Knäuper, V.: Relating matrix metalloproteinase structure to function: Why the 'hemopexin' domain. Matrix Biology, this issue.
30. Murphy G., Willenbrock F., Ward R.V., Cockett M.I., Eaton D., Docherty A.J. The C-terminal domain of 72 kDa gelatinase A is not required for catalysis, but is essential for membrane activation and modulates interactions with tissue inhibitors of metalloproteinases. Biochem. J. 283:1992;637-641.
31. Murray G.I., Duncan M.E., O'Neil P., Melvin W.T., Fothergill J.E. Matrix metalloproteinase-1 is associated with poor prognosis in colorectal cancer. Nat. Med. 2:1996;461-462.
32. Noël A., Lefebvre O., Maquoi E., VanHoorde L., Chenard M.P., Marcel M., Foidart J.M., Basset P., Rio M.C. Stromelysin-3 expression promotes tumor take in nude mice. J. Clin. Invest. 97:1996;1924-1930.
33. Nomura H., Sato H., Seiki M., Mai M., Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 55:1995;3263-3266.
34. Okada A., Bellocq J.P., Rouyer N., Chenard M.P., Rio M.C., Chambon P., Basset P. Membrane-type matrix metalloproteinase (MT-MMP) gene is expressed in stromal cells of human colon, breast, and head and neck carcinomas. Proc. Natl. Acad. Sci. USA. 92:1995;2730-2734.
35. Pei D., Weiss S.J. Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature. 375:1995;244-247.
36. Pei D., Weiss S.J. Transmembrane-deletion mutants of the membrane-type matrix metalloproteinase-1 process progelatinase A and express intrinsic matrix-degrading activity. J. Biol. Chem. 271:1996;9135-9140.
37. Polette M., Clavel C., Cockett M., Girod de Bentzmann S., Murphy G., Birembaut P. Detection and localization of mRNAs encoding matrix metalloproteinases and their tissue inhibitor in human breast pathology. Invasion Metastasis. 13:1993;31-37.
38. Polette M., Nawrocki B., Gilles C., Saro H., Seiki M., Tournier J.M., Birembaut P. MT-MMP expression and localisation in human lung and breast cancers. Virchows Arch. 428:1996;29-35.
39. Poulsom R., Pignatelli M., Stetler-Stevenson W.G., Liotta L.A., Wright P.A., Jeffery R.E., Longcroft J.M., Rogers L., Stamp G.W.H. Stromal expression of 72 kda type IV collagenase (MMP-2) and TIMP-2 mRNAs in colorectal neoplasia. Am. J. Pathol. 141:1992;389-396.
40. Puente X.S., Pendas A.M., Llano E., Velasco G., López-Otín C. Molecular cloning of a novel membrane-type matrix metalloproteinase from a human breast carcinoma. Cancer Res. 56:1996;944-949.
41. Pyke C., Ralfkiaer E., Tryggvason K., Danø K. Messenger RNA for two Type IV collagenases is located in stromal cells in human colon cancer. Am. J. Pathol. 142:1993a;359-365.
42. Pyke C., Graem N., Ralfkiaer E., Ronne E., Høyer-Hansen G., Brünner N., Danø K. Receptor for urokinase is present in tumor-associated macrophages in ductal breast carcinoma. Cancer Res. 53:1993b;1911-1915.
43. Santavicca M., Noël A., Angliker H., Stoll I., Segain J.P., Anglard P., Chretien M., Seidah N., Basser P. Characterization of structural determinants and molecular mechanisms involved in pro-stromelysin-3 activation by 4-aminophenylmercuric acetate and furin-type convertases. Biochem. J. 315:1996;953-958.
44. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 370:1994;61-65.
45. Stetler-Stevenson W.G., Hewitt R., Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Cancer Biol. 7:1996;147-154.
46. Strongin A.Y., Collier I., Bannikov G., Marmer B.L., Grants G.A., Goldberg G.I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloproteinase. J. Biol. Chem. 270:1995;5331-5338.
47. Takino T., Sato H., Shinagawa A., Seiki M. Identification of the second membrane-type matrix metalloproteinase (MT-MMP-2) gene from a human placenta cDNA library. J. Biol. Chem. 270:1995;23013-23020.
48. Will H., Hinzmann B. cDNA sequence and mRNA tissue distribution of a novel human matrix metalloproteinase with a potential transmembrane segment. Eur. J. Biochem. 231:1995;602-608.
49. Witty J.P., McDonnell S., Newell K.J., Cannon P., Navre M., Tressler R.J., Matrisian L.M. Modulation of matrilysin levels in colon carcinoma cell lines affect tumorigenicity in vivo. Cancer Res. 54:1994;4805-4812.
50. Wolf C., Rouyer N., Lurz Y., Adida C., Loriot M., Bellocq J.P., Chambon P., Basset P. Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression. Proc. Natl. Acad. Sci. USA. 90:1993;1843-1847.
51. Wolfsberg T.G., Primakoff P., Myles D.G., White J.M. ADAM, a novel family of membrane proteins containing a distingrin and metalloproteinase domain: multipotential functions in cell-cell and cell-matrix interactions. J. Cell Biol. 131:1995;275-278.